Cannabis News

benzinga

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021.

Philip Young, CEO and Director will begin his presentation at 10:30 A.M. ET on Wednesday, September 29, 2021.

The event is accessible using the following link: https://www.benzinga.com/events/small-cap/healthcare/september-29-track-1/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97705

News Provided by Newsfile via QuoteMedia

Lobe Sciences (CSE:LOBE,OTCQB: LOBEF)

Lobe Sciences


Keep reading...Show less

Centurion Provides Project Review and 2023 Plans; Announces Private Placement

Centurion Minerals Ltd. (TSXV: CTN) ("Centurion", or the "Company") wishes to summarize its 2022 achievements and provide an overview of its Canadian gold exploration project, 2023 plans, and objectives, as follows:

  1. Casa Berardi West Gold Project Acquisition: Proceeding with its original focus of acquiring and advancing gold exploration projects, the Company executed an Option Agreement in August 2022 to acquire a 100% interest in the Casa Berardi West Gold Project (the "Project"). The Project consists of 3 claim groups (Noseworthy, Newman and Hepburn) comprising a total of 4,700 hectares, strategically located northeast of Cochrane, Ontario, Canada in the mineral endowed central north Abitibi greenstone belt.

A NI 43-101 Technical Report outlining the Project's historical activities has been completed and can be found on the Company's website. (Casa Berardi West - Centurion Minerals Ltd).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

TerrAscend Closes on Acquisition of High-Performing Dispensary in Maryland

The 10,000 square foot Allegany Medical Marijuana Dispensary is located in Northwest Maryland within six miles of both the West Virgina and Pennsylvania borders

The acquisition complements TerrAscend's fully operational, state-of-the-art 150,000 square foot cultivation and processing facility in Hagerstown, MD and expands the Company's retail footprint to 32 dispensaries nationwide

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis plants with bitcoin

Cannabis Weekly Round-Up: Software Firm Pivots to Bitcoin Mining

In a surprising move, enterprise software firm Akerna (NASDAQ:KERN), which has developed programs to aid the cannabis industry, will merge with a Bitcoin miner and sell its software business to POSaBIT Systems (CSE:PBIT,OTCQX:POSAF).

Also this week, a Canadian cannabis operator received a warning from a leading exchange for its low trading numbers.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Curaleaf Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary

Stamford is Curaleaf's first dispensary in Connecticut to serve adult-use consumers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that it has been approved by the Connecticut Department of Consumer Protection to commence adult-use sales at its Stamford, Connecticut location, beginning Saturday, January 28 at 10:00 a.m. Curaleaf Stamford, located at 814 East Main St, is the Company's first dispensary in the state to open its doors to adult-use customers.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Marijuana Dispensary in Winter Haven, FL

New dispensary expands patient access to medical cannabis; grand opening specials available

Trulieve Cannabis Corp. (CSE: TRUL )(OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical dispensary in Winter Haven, Florida . Located at 6000 Cypress Gardens Blvd., the doors will open at 9 a.m. on Saturday, January 28 with ongoing regular hours of 9 a.m. 9 p.m. from Monday through Saturday and 10 a.m. 8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Announces Closure of Operations in California, Colorado and Oregon

Proactive Exit Will Generate Additional Cash and Improve Margins in Non-SAFE Banking Environment

2023 Free Cash Flow Expected to Exceed $125 Million

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×